What is anastrozole? What are the side effects? And am I eligible for the breast cancer drug? All your questions answered
Anastrozole, a breast cancer treatment drug, is now available to 289,000 women in England as a cancer preventative. Here, MailOnline answers your questions about the daily pill. (Source: the Mail online | Health)
Source: the Mail online | Health - November 7, 2023 Category: Consumer Health News Source Type: news
Anastrozole: Thousands to be offered drug to prevent breast cancer in England
Trials suggest anastrozole could reduce breast cancer cases by almost 50% in post-menopausal women. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 7, 2023 Category: Consumer Health News Source Type: news
Breakthrough 4p-a-day pill HALVES risk of getting breast cancer: Up to 300,000 at-risk women will be offered anastrozole on NHS in 'new era' of treatment that will save THOUSANDS of lives
The NHS will offer the hormone therapy anastrozole to 289,000 women deemed to be at moderate or high risk of breast cancer which could halve their risk of developing the disease. (Source: the Mail online | Health)
Source: the Mail online | Health - November 7, 2023 Category: Consumer Health News Source Type: news
Hundreds of thousands of woman will be offered daily pill that will HALVE their risk of developing breast cancer
The NHS will offer the hormone therapy anastrozole to 289,000 women deemed to be at moderate or high risk of breast cancer which could halve their risk of developing the disease. (Source: the Mail online | Health)
Source: the Mail online | Health - November 7, 2023 Category: Consumer Health News Source Type: news
Thousands of women to be offered drug to prevent breast cancer
Anastrozole, used for many years to treat breast cancer, has now been licensed as a preventative option. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 7, 2023 Category: Consumer Health News Source Type: news
Drug that can halve breast cancer risk offered to 289,000 women in England
Anastrozole to be made available to women who have been through the menopause and have family history of breast cancerAlmost 300,000 women at higher risk of developing breast cancer are being given access to a drug that can halve their risk in a “major step forward” in the fight against the disease.An estimated 289,000 women in England who are at moderate or high risk of breast cancer will from Tuesday be able to take the tablet to try to prevent it from developing, NHS bosses said.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 7, 2023 Category: Science Authors: Denis Campbell Health policy editor Tags: Breast cancer Health Society Drugs Science UK news Source Type: news
Chemotherapy Meets Its Match Against Aggressive ER+/HER2 – BRCAs Chemotherapy Meets Its Match Against Aggressive ER+/HER2 – BRCAs
In the phase 2 RIGHT Choice study, first-line ribociclib, combined with either letrozole or anastrozole plus goserelin, was associated with a doubling of progression-free survival.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
anastrozole
Title: anastrozoleCategory: MedicationsCreated: 8/5/2022 12:00:00 AMLast Editorial Review: 8/5/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 5, 2022 Category: Cancer & Oncology Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onc...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onco...
Source: Roche Investor Update - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Roche presents first phase II data on giredestrant, a next generation selective oestrogen receptor degrader, in untreated oestrogen receptor (ER)-positive, early breast cancer
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim data from the randomised phase II coopERA Breast Cancer trial evaluating neoadjuvant treatment with giredestrant (formerly known as GDC-9545), an investigational next generation oral selective oestrogen receptor degrader (SERD), in post-menopausal women with ER-positive, HER2-negative early breast cancer. In the window of opportunity phase, after 14 days of treatment, giredestrant showed a reduction in Ki67, a prognostic marker that measures tumour proliferation, compared to anastrozole (80% versus 67% respectively, p=0.0222). The safety ...
Source: Roche Investor Update - September 17, 2021 Category: Pharmaceuticals Source Type: news
Five - Year Extended Hormone Therapy No Better in Breast Cancer
Findings compared with two years of extended adjuvant anastrozole in postmenopausal women with hormone - receptor - positive breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 29, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Pharmacy, Journal, Source Type: news
Bone density loss from Anastrozole partially reverses after treatment stops
(Queen Mary University of London) A study by researchers from Queen Mary University of London shows that bone loss known to be associated with the use of the breast cancer prevention drug Anastrozole partially reverses, particularly at the lumbar spine, after stopping treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 21, 2021 Category: Cancer & Oncology Source Type: news
